(secondQuint)VNP40101M in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome.

 OBJECTIVES: - Determine the toxic effects of VNP40101M in patients with relapsed or refractory leukemia or poor-risk myelodysplastic syndromes.

 - Determine the maximum tolerated dose of this drug in these patients.

 - Determine the pharmacokinetics of this drug in these patients.

 - Determine the antitumor effects of this drug in these patients.

 OUTLINE: Patients receive VNP40101M IV over 15 minutes once every 4 weeks.

 PROJECTED ACCRUAL: Approximately 40 patients will be accrued for this study.

.

 VNP40101M in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome@highlight

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.

 PURPOSE: Phase I trial to study the effectiveness of VNP40101M in treating patients who have relapsed or refractory leukemia or myelodysplastic syndrome.

